Xenon Pharmaceuticals (FRA:XP0) Total Stockholders Equity : €816.68 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Total Stockholders Equity?

Xenon Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €816.68 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Xenon Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €10.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Xenon Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.01.

Xenon Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Xenon Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Total Stockholders Equity Chart

Xenon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

82.78

140.85

486.78

681.09

850.90

Xenon Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															641.61	596.68	596.49	850.90	816.68

Xenon Pharmaceuticals (FRA:XP0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Xenon Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(816.682	-	0)	/	75.4597
	=	10.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Xenon Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.217	+	8.374)	/	816.682
	=	0.01

Xenon Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenon Pharmaceuticals (FRA:XP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (FRA:XP0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

XENE:USA

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Xenon Pharmaceuticals (FRA:XP0) Headlines

No Headlines